Novo Nordisk has introduced an innovative subscription program for its Wegovy obesity treatment, aimed at providing cash-paying patients with more affordable and predictable monthly costs. This initiative, launched on Tuesday, allows eligible patients to select from subscriptions lasting three, six, or twelve months for either the Wegovy injection or the two highest doses of the newly released oral tablet bearing the same name.
The longer the subscription period chosen, the lower the monthly cost, with potential annual savings of up to $1,200 for the injection and $600 for the oral pill when compared to paying for doses individually each month. Patients will benefit from a fixed monthly price even if they adjust their dosage within the subscription.
This subscription service is accessible through several of Novo’s telehealth partners, including Ro, WeightWatchers, LifeMD, Sesame, and Hims & Hers, with more collaborators expected to join the initiative soon. Ed Cinca, Novo’s head of marketing and patient solutions, emphasizes that this program offers a significant opportunity for patients to not only initiate but also maintain their treatment, addressing common concerns related to medication pricing, especially in the context of potential fluctuations.
Adherence to GLP-1 medications like Wegovy has historically posed challenges for patients due to issues ranging from accessibility to side effects, with studies indicating that approximately 65% of individuals with obesity discontinue treatment within a year. The new subscription program aims to mitigate these issues, thereby enhancing patient commitment to long-term obesity management.
The pricing structure for the Wegovy products under the subscription plan is as follows:
Injection Plans (0.25, 0.5, 1.7, and 2.4 milligram doses):
- 3-month: $329 per month (annual savings of $240)
- 6-month: $299 per month (annual savings of $600)
- 12-month: $249 per month (annual savings of $1,200)
Pill Plans (9 and 25 milligram doses):
- 3-month: $289 per month (annual savings of $120)
- 6-month: $269 per month (annual savings of $360)
- 12-month: $249 per month (annual savings of $600)
The launch of this subscription program coincides with increasing demand for the Wegovy pill, which has garnered significant attention since its U.S. introduction in January. However, the company faces impending competition from an oral GLP-1 treatment by Eli Lilly, its main competitor in the market, which currently commands around 60% market share compared to Novo’s 39%. Capturing new patients is essential for Novo prior to Lilly’s anticipated product launch.
For patients who may still prefer alternative options, the lower doses of the Wegovy pill (1.5 and 4 milligrams) are currently available at $149 per month; however, this price will increase to $199 starting in August for the 4-milligram dose. The newly approved 7.2-milligram dose will be incorporated into the subscription program in the future.
Cinca reassures patients that they can opt out of the subscription at any time if they no longer wish to continue. He commented on the company’s commitment to creating treatment pathways that foster long-term comfort and adherence to managing obesity. While the subscription plan is not yet available through Novo’s own direct-to-consumer pharmacy, there are plans to evaluate the program’s success to enhance future offerings through that channel.
